Kristin Robin Villalon Harrington, M.D.,Ph.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacies | 5 | 2024 | 171 | 1.200 |
Why?
|
| Contact Tracing | 2 | 2024 | 274 | 0.880 |
Why?
|
| Pharmaceutical Services | 1 | 2023 | 145 | 0.770 |
Why?
|
| Pharmacy | 1 | 2023 | 92 | 0.760 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2019 | 45 | 0.620 |
Why?
|
| Chickenpox | 1 | 2019 | 95 | 0.600 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2024 | 941 | 0.590 |
Why?
|
| HIV Infections | 8 | 2024 | 17542 | 0.530 |
Why?
|
| Lung Diseases | 1 | 2021 | 1942 | 0.360 |
Why?
|
| Georgia | 2 | 2024 | 186 | 0.260 |
Why?
|
| Community Pharmacy Services | 1 | 2024 | 52 | 0.230 |
Why?
|
| Carbapenems | 1 | 2024 | 125 | 0.220 |
Why?
|
| beta-Lactamases | 1 | 2024 | 307 | 0.200 |
Why?
|
| Heroin Dependence | 1 | 2023 | 173 | 0.200 |
Why?
|
| Quarantine | 1 | 2024 | 186 | 0.200 |
Why?
|
| Universities | 2 | 2024 | 1004 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 1969 | 0.170 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 1695 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2024 | 689 | 0.160 |
Why?
|
| South Africa | 1 | 2024 | 1873 | 0.150 |
Why?
|
| Communicable Disease Control | 1 | 2024 | 856 | 0.140 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 668 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2024 | 1277 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2024 | 2353 | 0.130 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2015 | 84 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 3232 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2024 | 5311 | 0.110 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1761 | 0.100 |
Why?
|
| Students | 1 | 2022 | 1744 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2016 | 592 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 3834 | 0.090 |
Why?
|
| Pandemics | 3 | 2024 | 8736 | 0.080 |
Why?
|
| Humans | 19 | 2024 | 767040 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2022 | 3797 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 2188 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2022 | 5345 | 0.070 |
Why?
|
| Male | 12 | 2024 | 364203 | 0.070 |
Why?
|
| Antitubercular Agents | 1 | 2016 | 1380 | 0.070 |
Why?
|
| Young Adult | 5 | 2024 | 59980 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2015 | 1806 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 7469 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 26325 | 0.060 |
Why?
|
| Hospitals | 1 | 2019 | 3883 | 0.060 |
Why?
|
| Middle Aged | 7 | 2024 | 223233 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2016 | 1911 | 0.060 |
Why?
|
| Homosexuality, Male | 2 | 2023 | 1344 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2021 | 4746 | 0.060 |
Why?
|
| Adult | 7 | 2024 | 223317 | 0.060 |
Why?
|
| Smoking | 1 | 2021 | 9081 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 54886 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 61 | 0.050 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2024 | 190 | 0.050 |
Why?
|
| Heroin | 1 | 2023 | 120 | 0.050 |
Why?
|
| Hospitalization | 1 | 2022 | 10815 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 41718 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2024 | 996 | 0.050 |
Why?
|
| Pseudomonas Infections | 1 | 2024 | 623 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2024 | 530 | 0.040 |
Why?
|
| United States | 3 | 2024 | 72971 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2024 | 1830 | 0.040 |
Why?
|
| Adolescent | 2 | 2024 | 89046 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2024 | 1023 | 0.040 |
Why?
|
| Female | 8 | 2024 | 396660 | 0.040 |
Why?
|
| Philippines | 1 | 2016 | 95 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2024 | 2505 | 0.030 |
Why?
|
| Educational Status | 1 | 2022 | 2511 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2024 | 2196 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2015 | 217 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2022 | 2116 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2015 | 371 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 2783 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 36582 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8732 | 0.020 |
Why?
|
| Poverty | 1 | 2022 | 2719 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3212 | 0.020 |
Why?
|
| Genotype | 1 | 2024 | 13035 | 0.020 |
Why?
|
| Critical Illness | 1 | 2022 | 2753 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 2221 | 0.020 |
Why?
|
| Mass Screening | 1 | 2024 | 5456 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 14672 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2022 | 81659 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2444 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 3837 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 14766 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 1895 | 0.020 |
Why?
|
| Lung | 1 | 2024 | 10076 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6310 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2015 | 3324 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 20741 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8068 | 0.010 |
Why?
|
| Time Factors | 1 | 2022 | 40154 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2015 | 14476 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 22361 | 0.010 |
Why?
|
| Child | 1 | 2022 | 80771 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 65295 | 0.000 |
Why?
|
| Aged | 1 | 2022 | 171319 | 0.000 |
Why?
|
| Risk Factors | 1 | 2016 | 74886 | 0.000 |
Why?
|
| Mice | 1 | 2015 | 81912 | 0.000 |
Why?
|
| Animals | 1 | 2015 | 168965 | 0.000 |
Why?
|